• SAKURA 3: DaxibotulinumtoxinA for injection shows consistent efficacy in open-label study

    7 days ago - By Healio

    In an open-label study, daxibotulinumtoxinA for injection demonstrated efficacy and safety outcomes in moderate or severe glabellar lines that were comparable to previous findings.
    Sabrina G. Fabi, MD, of the University of California, San Diego, and Cosmetic Laser Dermatology in San Diego, and colleagues wrote that daxibotulinumtoxinA for injection is a botulinum toxin type A formulated with a novel peptide excipient. “Two pivotal, single-treatment, placebo-controlled trials demonstrated efcacy and safety for moderate or severe glabellar lines,” they wrote.
    In the
    Read more ...